Women's Health

Do GLP-1 medications affect birth control, and how long before pregnancy should they be stopped?

Tirzepatide and semaglutide carry opposite warnings, and almost every article on this subject blurs them together. Tirzepatide can reduce absorption of oral contraceptives, and its label requires switching to a non-oral method or adding a barrier method for four weeks after starting and four weeks after every dose increase. Semaglutide carries no contraceptive warning at all — the interaction was studied and found not clinically relevant. Reverse that for pregnancy planning: semaglutide labels advise stopping at least two months before a planned pregnancy, while tirzepatide labels specify no washout period.

How do GLP-1s affect women specifically — PCOS, fertility, and contraception?

GLP-1s are unusually well-studied in women. They improve weight, insulin resistance, and often menstrual regularity in PCOS; they can restore ovulation (so unplanned pregnancy is a real risk); and they carry a hard pre-conception stop because of their long washout. They are not a fertility drug — the fertility effect is a downstream consequence of weight and metabolic improvement.

Will kisspeptin and other emerging peptides actually help female sexual health, and when?

Yes — eventually. Kisspeptin targets the upstream hypothalamic GnRH/sexual-arousal circuit, distinct from PT-141 (dopaminergic) and flibanserin (serotonergic). Phase 2 data shows brain-activation and subjective response improvements, including in postmenopausal women. Not currently a clinical option. Realistic availability 2027-2030. Today's options remain PT-141, flibanserin, off-label testosterone, oxytocin.

What's the best skincare protocol for menopausal skin thinning and collagen loss?

Estrogen loss drives ~30% collagen decline in the first five years post-menopause, plus dermal-epidermal junction flattening, hyaluronic-acid depletion, and reduced sebum. Standard anti-aging skincare under-performs because it targets cell turnover, not structure. Topical peptides (GHK-Cu 2–3% twice daily, Matrixyl 3000) plus mineral SPF outperform retinoid monotherapy — visible results at weeks 9–12.

Should I time peptides to my menstrual cycle, and what changes across phases?

The menstrual cycle changes the hormonal background peptides act on, so the same protocol can feel different across phases. But evidence for deliberately timing peptides to cycle phase is thin — track and observe rather than chase a schedule. The one hard rule is reproductive intent: if a cycle could end in conception, pregnancy-safety rules take over.

Can peptides help with perimenopause and menopause, and which ones are worth it?

Falling estrogen shifts body composition, skin, sleep, and bone, which is why peptide interest spikes in menopause. Peptides don't replace evidence-based menopause care or hormone therapy, but a few have a plausible supporting role: GLP-1s for the metabolic and weight changes (real data), and topical skin peptides for estrogen-related skin loss (weaker data). Systemic collagen claims deserve skepticism.

Which peptides are safe in pregnancy and breastfeeding, and what should I stop?

No peptide has adequate human safety data in pregnancy or breastfeeding, so the responsible default is avoidance. GLP-1s need a planned pre-conception stop because of their long washout. For research peptides with no pregnancy data at all, 'we don't know' should be read as 'don't' — the risk is asymmetric and the intervention is deferrable.

Which peptides actually help women with low libido or sexual dysfunction, and what's the evidence?

PT-141 (Vyleesi) is FDA-approved for premenopausal HSDD — the only sexual-health peptide with female-specific approval. Kisspeptin shows promising early human evidence for female desire. Oxytocin has mixed data. The female sexual-health peptide space is actually better-evidenced than the male space because PT-141's approval was for women.